Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go:
Extended
investment:
£10,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go:
Extended
investment:
Withheld
Helping SME home builders acquire finance for their projects in the UK. Rubicon Capital has assisted more than 40 project developers in receiving investments for their builds, which has exceeded £75m. In their second year, the company generated £500k in profits and has successfully paid dividends every year since launching in 2015. Two main sources of revenue are upfront fees for connecting borrowers with lenders and administration fees in the form of long-term consultancy and performance assistance.
Money raised from this crowdfunding round will be used to expand the Rubicon Capital team and grow their business to attract more home builders requiring financial assistance, in addition to increasing the number of sources offering finance.
days to go:
Expired
investment:
£128,510
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.
days to go:
Expired
investment:
£290,278
Delivering safe and clean drinking water by using nanotechnology to produce eco-friendly and recyclable filters. Water to Go has developed a portable 750ml filter that is equivalent to using more than 400 water bottles designed for single-use and made from plastic.
Water to Go's technology has been tested in multiple laboratories across the globe and the company has planned to integrate their product into more applications. Their filter initially launched on Amazon.com and is currently available in over 50 countries worldwide. Clients include Boots, Millets, Go Outdoors and Blacks amongst others. Repeat sales of the filter is currently the main source of revenue.
days to go:
Expired
investment:
£276,580
Viritech is a clean technology engineering company that is using F1-derived engineering to develop hydrogen powertrain solutions and related technologies for the automotive, aerospace, marine and distributed power industries. Viritech asserts that the Hydrogen Council forecasts that hydrogen will meet 18% of global energy demand by 2050. It aims to capture this demand through its technologies. Viritech argues that its location in MIRA Technology Park allows it access to R&D facilities used by many of the world's major automotive manufacturers, allowing it to scale its resources to meet the demands of every type of project. Viritech will use the investment to produce test hydrogen tanks, build the Apricale hypercar, complete designs for a Heavy Goods Vehicle (HGV), Sport Utility Vehicle (SUV) and a power generator, plan a larger raise and listing on AQuis Stock Exchange (AQSE) in 2022, and eventually commercialise its technology with its partner.
days to go:
Expired
investment:
£726,807
Next-generation wellbeing analytics for individuals and organisations – boosts happiness and productivity
days to go:
Expired
investment:
£768,597
